### IN THE UNITED STATES PATENT & TRADEMARK OFFICE

In Re the Application of:	Group Art Unit: Not yet assigned
Alberto et al.	Examiner: Not yet assigned
Serial No.: 10/576,839 )	
Filed: April 20, 2006	
Atty. File No.: 1621 WO/US	
Title: Use of Metal Tricarbonyl Complexes ) as Radiotherapeutic Chemotoxic ) Agents	

### SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Dear Sir:

In accordance with duties imposed by 37 CFR §1.56 and means for complying therewith according to 37 CFR §§1.97-1.98, the references listed on the attached Form PTO/SB/08A are called to the attention of the US Patent & Trademark Office in relation to the present application.

No representation is made that the cited references are the only art or that the cited references represent the best art. The Examiner is urged to consider all of the cited references and to make an independent evaluation of the teachings and materiality of each.

Since this correspondence is being submitted after a first Office Action on the merits pursuant to 37 C.F.R. §1.97(c)(2), a fee of \$180.00 is due. Please charge the appropriate fee to Deposit Account No. 13-1160.

Respectfully submitted,

Drang R. Komm

Anthony R. Kinney

tony.kinney@covidien.com

314-654-8346

Doc code: IDS

Doc description: Information Disclosure Statement (IDS) Filed

PTO/SB/08a (01-10)
Approved for use through 07/31/2012. OMB 0651-0031

Mation Disclosure Statement (IDS) Filed
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	Application Number		10576839	
	Filing Date		2006-04-20	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	First Named Inventor Albert		perto	
	Art Unit		1618	
	Examiner Name Dam		Dameron Levest Jones	
	Attorney Docket Number		1621 WO/US	

				l	U.S.F	ATENTS				
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	9	Name of Pate of cited Docu	entee or Applicant ment	Relev	s,Columns,Lines where vant Passages or Relev es Appear	
	1									
If you wisl	h to ac	ld additional U.S. Pa	ent citatio	n information	on pl	ease click the	Add button.			
			U.S.P	ATENT AF	PLIC	CATION PUB	LICATIONS			
Examiner Initial*	Cite I	No Publication Number	Kind Code <sup>1</sup>	Publicatio Date	n	Name of Patentee or Applicant Relev		ages,Columns,Lines where elevant Passages or Relevant igures Appear		
	1									
If you wis	h to ac	ld additional U.S. Pu	blished A	plication ci	itation	n information p	olease click the Ad	d butte	on.	
				FOREIGN	PAT	ENT DOCUM	IENTS			·
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Countr Code <sup>2</sup>	<i>-</i>	ind ode4	Publication Date	Name of Patente Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T5
	1					·				
If you wis	h to ac	ld additional Foreign	Patent Do	ocument cit	tation	information p	lease click the Add	butto	n	
<u> </u>						RATURE DC	· · · · · · · · · · · · · · · · · · ·			
Examiner Initials*	Cite No	Include name of the (book, magazine, jo publisher, city and/o	urnal, ser	ial, sympos	sium,	catalog, etc),	the article (when a date, pages(s), vo	approp lume-is	oriate), title of the item ssue number(s),	Ţ⁵

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

( Not for submission under 37 CFR 1.99)

•		
Application Number		10576839
Filing Date		2006-04-20
First Named Inventor	Alber	rto
Art Unit		1618
Examiner Name	Dam	eron Levest Jones
Attorney Docket Numb	er	1621 WO/US

	1	oganson A A (1985) "Metal Carbonyl Complexes with Ligands of Biological Origin" Russian Chemical Reviews vol. 54, no. 3, pp. 277-292						
	2	Severin et al. (June 1, 1998) "Bioorganometallic Chemistry-Transition Metal Complexes with α- Amino Acids and Peptides" vol. 37, no. 12, pp. 1635-1654						
	3	Egli et al. (January 1, 1999) "Organometallic 99mTc-Aquaion Labels Peptide to an Unprecedented High Specific Activity" vol. 40, no. 11, pp. 1913-1917						
	Du J et al. (August 1, 2001) "Technetium-99m labelling of glycosylated somatostatin-14" vol. 55, no. 2, pp. 181-187							
If you wis	h to a	l additional non-patent literature document citation information please click the Add button						
		EXAMINER SIGNATURE						
Examiner	Examiner Signature Date Considered							
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								
<sup>1</sup> See Kind Codes of USPTO Patent Documents at <u>www.USPTO.GOV</u> or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.								

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

( Not for submission under 37 CFR 1.99)

Application Number		10576839	
Filing Date		2006-04-20	
First Named Inventor Albert		to	
Art Unit		1618	
Examiner Name Dame		eron Levest Jones	
Attorney Docket Number		1621 WO/US	

CERTIFICATION STATEMENT								
Plea	Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):							
	That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).							
OR	OR							
	That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).							
	See attached certification statement.							
	The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.							
	A certification statement is not submitted herewith.  SIGNATURE  A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.							
Signature		/Anthony R. Kinney, reg. no. 44834/ Date (YYYY-MM-DD)		2011-10-26				
Nar	ne/Print	Anthony R. Kinney	Registration Number	44,834				

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.** 

#### **Privacy Act Statement**

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

- 1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
- A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
- 3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
- 4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
- A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
  may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
  to the Patent Cooperation Treaty.
- 6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
- 9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.